PHILADELPHIA, PA — Century Therapeutics (NASDAQ: IPSC) has announced it will host a conference call and live audio webcast on Monday, December 11, to discuss preliminary clinical data from its ongoing Phase 1 ELiPSE-1 trial. The trial is testing CNTY-101, the firm’s lead allogeneic, iPSC-derived CAR-iNK cell therapy, in patients with relapsed or refractory CD19 positive B-cell lymphomas.
The conference call will include updated preliminary clinical data from a case study presented at the 65th American Society of Hematology Annual Meeting. Additionally, Century Therapeutics will share results from patients treated at Dose Level 1 (100 million cell dose), along with preliminary data from patients treated at Dose Level 2 (300 million cell dose).
The company will also outline its plans for a Phase 1 trial of CNTY-101 in systemic lupus erythematosus, marking the first autoimmune and inflammatory disease indication for the therapy. This discussion will include supporting preclinical data.
The conference call and live audio webcast, complete with accompanying slides, will be accessible through the Events & Presentations page in the Investors section of the company’s website. Those unable to participate in real-time can access a replay on Century Therapeutics’ website about 24 hours after the conference call, which will remain available for 90 days.
The announcement comes as Century Therapeutics’ stock sees an uptick in trading. The focus now turns to the upcoming conference call, where investors will closely monitor the discussed clinical data and future plans for CNTY-101.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.